×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVCT – nuvectis pharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVCT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/2
08:31 am
nvct
Nuvectis Pharma, Inc. (NASDAQ: NVCT) is now covered by analysts at Maxim Group. They set a "buy" rating and a $17.00 price target on the stock.
Medium
Report
Nuvectis Pharma, Inc. (NASDAQ: NVCT) is now covered by analysts at Maxim Group. They set a "buy" rating and a $17.00 price target on the stock.
3/26
08:00 am
nvct
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
Medium
Report
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
3/17
08:11 am
nvct
Nuvectis Pharma, Inc. (NASDAQ: NVCT) is now covered by analysts at Laidlaw. They set a "buy" rating and a $19.00 price target on the stock.
Medium
Report
Nuvectis Pharma, Inc. (NASDAQ: NVCT) is now covered by analysts at Laidlaw. They set a "buy" rating and a $19.00 price target on the stock.
3/14
08:00 am
nvct
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
Low
Report
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
3/5
08:44 am
nvct
Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
Low
Report
Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
3/4
08:00 am
nvct
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
Medium
Report
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
2/27
11:25 am
nvct
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets [Yahoo! Finance]
Low
Report
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets [Yahoo! Finance]
2/27
10:43 am
nvct
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
Low
Report
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/25
04:06 pm
nvct
Form 10-K Nuvectis Pharma, Inc. For: Dec 31
Low
Report
Form 10-K Nuvectis Pharma, Inc. For: Dec 31
2/25
09:26 am
nvct
Form 8-K Nuvectis Pharma, Inc. For: Feb 25
Low
Report
Form 8-K Nuvectis Pharma, Inc. For: Feb 25
2/11
05:59 pm
nvct
Form 4 Nuvectis Pharma, Inc. For: Feb 07 Filed by: Mosseri Marlio Charles
Medium
Report
Form 4 Nuvectis Pharma, Inc. For: Feb 07 Filed by: Mosseri Marlio Charles
2/6
06:30 am
nvct
Form 424B5 Nuvectis Pharma, Inc.
Medium
Report
Form 424B5 Nuvectis Pharma, Inc.
2/6
06:01 am
nvct
Form 8-K Nuvectis Pharma, Inc. For: Feb 05
Medium
Report
Form 8-K Nuvectis Pharma, Inc. For: Feb 05
2/4
04:31 pm
nvct
Form 424B5 Nuvectis Pharma, Inc.
Medium
Report
Form 424B5 Nuvectis Pharma, Inc.
1/3
06:13 pm
nvct
Form 4 Nuvectis Pharma, Inc. For: Jan 02 Filed by: Shemesh Shay
High
Report
Form 4 Nuvectis Pharma, Inc. For: Jan 02 Filed by: Shemesh Shay
1/3
06:12 pm
nvct
Form 4 Nuvectis Pharma, Inc. For: Jan 02 Filed by: Poradosu Enrique
High
Report
Form 4 Nuvectis Pharma, Inc. For: Jan 02 Filed by: Poradosu Enrique
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: